Spravato Treatment at New Life Midwest: A Breakthrough for Treatment-Resistant Depression
Why Choose Spravato?
• Rapid Relief: Spravato® can deliver noticeable improvements in depressive symptoms as early as 24 hours after the first dose, offering a faster alternative to traditional treatments.
• Personalized Care: It can be used as a standalone therapy or in combination with oral antidepressants, allowing for tailored treatment plans based on individual needs and tolerability.
• Proven Effectiveness: Clinical studies have shown that Spravato® significantly reduces symptoms of depression and helps prevent relapses when used consistently
At New Life Midwest, we are proud to offer Spravato® (esketamine), an FDA-approved nasal spray designed to provide rapid relief for adults struggling with treatment-resistant depression (TRD) or major depressive disorder (MDD) with acute suicidal ideation or behavior. This innovative therapy represents a new hope for patients who have not responded to traditional antidepressants.
Who Can Benefit?
Spravato® is ideal for adults who:
• Have not found relief after trying at least two other antidepressant therapies.
• Struggle with severe depressive symptoms that interfere with daily life.
• Require an alternative due to side effects or limited effectiveness of traditional medications.
